Zhang Y, McAlindon T E, Hannan M T, Chaisson C E, Klein R, Wilson P W, Felson D T
Boston University School of Medicine, Massachusetts, USA.
Arthritis Rheum. 1998 Oct;41(10):1867-73. doi: 10.1002/1529-0131(199810)41:10<1867::AID-ART20>3.0.CO;2-W.
To examine whether estrogen replacement therapy (ERT) prevents worsening of radiographic knee osteoarthritis (OA) in elderly women.
A total of 551 women ages 63-91 years (mean age 71) in the Framingham Study were followed up from biennial examination 18 (1983-1985) to examination 22 (1992-1993). Data on postmenopausal ERT were obtained every 2 years. Subjects were classified into 3 groups according to their estrogen use at biennial examination 18: never users (n = 349), past users (n = 162), and current users (n = 40). Women received anteroposterior weight-bearing knee radiographs at examinations 18 and 22. Using the Kellgren and Lawrence criteria, global radiographic knee OA was assessed, (grade range 0-4) and individual radiographic features, such as osteophytes and joint space narrowing, were scored from 0 to 3. Worsening was defined as either development of radiographic OA that was not present at baseline (incident OA) or progression of baseline radiographic OA by > or =1 Kellgren and Lawrence grade (progressive OA). Potential confounding factors included age, body mass index, weight change, smoking, knee injury, physical activity level, and bone mineral density at the femoral neck.
During 8 years of followup, 17.4% of knee radiographic scores worsened by 1 grade and 5.8% by 2 or 3 grades among never users of ERT. Among current estrogen users, only 11.7% of knee radiographic scores worsened by 1 grade and none worsened by more than 1 grade. After adjusting for age and other potential confounding factors, the relative risk of incident radiographic knee OA in comparison with never users of estrogen was 0.8 (95% confidence interval [95% CI] 0.5-1.4) in past users and 0.4 (95% CI 0.1-3.0) in current users. Current use of estrogen also showed a trend toward decreased risk of progressive knee OA compared with never use (odds ratio [OR] 0.5, 95% CI 0.1-2.9). When both incident and progressive radiographic knee OA cases were combined, current ERT use had a 60% decreased risk compared with never use (OR 0.4, 95% CI 0.1-1.5).
This is the first prospective cohort study to examine the effects of ERT on radiographic knee OA. The results indicate that current use of ERT had a moderate, but not statistically significant, protective effect against worsening of radiographic knee OA among elderly white women. These findings corroborate those of cross-sectional studies and point further to a potential benefit of female hormones in OA.
探讨雌激素替代疗法(ERT)是否能预防老年女性膝关节影像学骨关节炎(OA)的恶化。
在弗雷明汉研究中,共有551名年龄在63 - 91岁(平均年龄71岁)的女性从第18次两年一次的检查(1983 - 1985年)随访至第22次检查(1992 - 1993年)。每两年获取一次绝经后ERT的数据。根据她们在第18次两年一次检查时的雌激素使用情况,将受试者分为3组:从未使用者(n = 349)、过去使用者(n = 162)和当前使用者(n = 40)。女性在第18次和第22次检查时接受膝关节前后位负重X线片检查。使用凯尔格伦和劳伦斯标准评估膝关节整体影像学OA(分级范围0 - 4级),并对诸如骨赘和关节间隙变窄等个体影像学特征从0到3进行评分。恶化定义为基线时不存在的影像学OA的出现(新发OA)或基线影像学OA进展≥1个凯尔格伦和劳伦斯分级(进展性OA)。潜在的混杂因素包括年龄、体重指数、体重变化、吸烟、膝关节损伤、身体活动水平以及股骨颈骨密度。
在8年的随访期间,ERT从未使用者中17.4%的膝关节影像学评分恶化1级,5.8%恶化2级或3级。在当前雌激素使用者中,只有11.7%的膝关节影像学评分恶化1级,且无恶化超过1级的情况。在调整年龄和其他潜在混杂因素后,与从未使用雌激素者相比,过去使用者发生影像学膝关节OA的相对风险为0.8(95%置信区间[95%CI]0.5 - 1.4),当前使用者为0.4(95%CI 0.1 - 3.0)。与从未使用相比,当前使用雌激素在进展性膝关节OA风险降低方面也呈现出一种趋势(优势比[OR]0.5,95%CI 0.1 - 2.9)。当将新发和进展性影像学膝关节OA病例合并时,与从未使用相比,当前使用ERT的风险降低了60%(OR 0.4,95%CI 0.1 - 1.5)。
这是第一项前瞻性队列研究,旨在探讨ERT对膝关节影像学OA的影响。结果表明,当前使用ERT对老年白人女性膝关节影像学OA的恶化具有中等程度但无统计学意义的保护作用。这些发现证实了横断面研究的结果,并进一步指出女性激素在OA中可能具有益处。